Research and Conference Publications
Permanent URI for this collectionhttps://hdl.handle.net/10137/12691
This collection contains journal articles and other research publications such as book chapters, conference papers, and posters authored by NT Health staff and provides an overview of the interests, research activities and projects undertaken by NT Health staff. Most journal articles are published in subscription-based or open access publications, so this collection contains mainly citations and links to full text content on external sites, but where permitted, the PDF file has been made available.
Browse
Browsing Research and Conference Publications by Title
Now showing 1 - 20 of 2190
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Journal ArticlePublication 10-Valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trial.(2020-05-24) ;Oguoma VM ;Wilson N ;Mulholland K ;Santosham M ;Torzillo P ;McIntyre P ;Smith-Vaughan H ;Balloch A ;Chatfield M ;Lehmann D ;Binks MJ ;Chang Anne ;Carapetis JR; ;Andrews RM ;Snelling T ;Licciardi P ;Morris PeterLeach AJINTRODUCTION: Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) are major otitis media pathogens that densely co-colonise the nasopharynx and infect the middle ear of Australian Aboriginal infants from very early in life. Our co-primary hypotheses are that at 18 months of age infants receiving 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) compared with those receiving 13-valent pneumococcal conjugate vaccine (PCV13) as a booster at 12 months of age will have higher antibody levels to Haemophilus influenzae protein D and that infants receiving PCV13 will have higher antibody levels to PCV13-only serotypes 3, 6A and 19A. METHODS AND ANALYSES: Our randomised controlled trial will enrol 270 Aboriginal children at 12 months of age to a booster dose of either PHiD-CV10 or PCV13. Children who completed the three-dose primary course schedules of PHiD-CV10 at 2, 4, 6 months of age; PCV13 at 2, 4, 6 months of age; or a combination schedule of PHiD-CV10 at 1, 2, 4 months of age plus PCV13 at 6 months of age are eligible. The co-primary assessor-blinded outcomes when the infants are 18 months of age are as follows: (a) IgG geometric mean concentration (GMC) and proportion with IgG ≥100 EU/mL for protein D, and (b) IgG GMC and the proportion with IgG ≥0.35 µg/mL for pneumococcal serotypes 3, 6A and 19A. Secondary immunogenicity comparisons of six primary and booster dose schedules of 10 shared serotypes at 18 months of age, nasopharyngeal carriage, all forms of otitis media, hearing loss and developmental milestones at 18, 24, 30 and 36 months of age will be reported. ETHICS AND DISSEMINATION: Ethics committees of NT Department of Health, Menzies, WA Department of Health and WA Aboriginal Health approved the study. Results will be presented to communities, at conferences and published in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT01735084.14740 - Some of the metrics are blocked by yourconsent settings
Journal ArticlePublication A 16-year prospective study of community-onset bacteremic Acinetobacter pneumonia: low mortality with appropriate initial empirical antibiotic protocols.The genus Acinetobacter, well known as a nosocomial pathogen, can also cause severe community-onset pneumonia. Previous small case series have suggested fulminant disease and a pooled hospital mortality of > 60%. We conducted a prospective observational study of all episodes of bacteremic, community-onset, and radiologically confirmed pneumonia due to Acinetobacter species at a tertiary referral hospital in tropical Australia from 1997 to 2012 following the introduction of routine empirical treatment protocols covering Acinetobacter. Demographic, clinical, microbiologic, and outcome data were collected. There were 41 episodes of bacteremic community-onset Acinetobacter pneumonia, of which 36 had no indicators suggesting health-care-associated infection. Of these, 38 (93%) were Indigenous Australians, one-half were men, the average age was 44.1 years, and 36 episodes (88%) occurred during the rainy season. All patients had at least one risk factor, with hazardous alcohol intake in 82%. Of the 37 isolates available for molecular speciation, 35 were Acinetobacter baumannii and two were Acinetobacter nosocomialis. All isolates were susceptible in vitro to gentamicin, meropenem, and ciprofloxacin, but only one was fully susceptible to ceftriaxone. ICU admission was required in 80%. All 41 patients received appropriate antibiotics within the first 24 h of admission, and 28- and 90-day mortality were both low at 11%. Community-acquired Acinetobacter pneumonia is a severe disease, with the majority of patients requiring ICU admission. Most patients have risk factors, particularly hazardous alcohol use. Despite this severity, correct initial empirical antibiotic therapy in all patients was associated with low mortality.16547 - Some of the metrics are blocked by yourconsent settings
Journal ArticlePublication An 18 year clinical review of septic arthritis from tropical Australia.(1996-12) ;Morgan DS ;Fisher D ;Merianos AA retrospective study of 191 cases of septic arthritis was undertaken at Royal Darwin Hospital in the tropical north of Australia. Incidence was 9.2 per 100,000 overall and 29.1 per 100,000 in Aboriginal Australians (RR 6.6; 95% CI 5.0-8.9). Males were affected more than females (RR 1.6; 95% CI 1.2-2.1). There was no previous joint disease or medical illness in 54%. The commonest joints involved were the knee (54%) and hip (13%). Significant age associations were infected hips in those under 15 years and infected knees in those over 45 years. Seventy two percent of infections were haematogenous. Causative organisms included Staphylococcus aureus (37%), Streptococcus pyogenes (16%) and Neisseria gonorrhoeae (12%). Unusual infections included three melioidosis cases. Polyarthritis occurred in 17%, with N. gonorrhoeae (11/23) more likely to present as polyarthritis than other organisms (22/168) (OR 6.0; 95% CI 2.1-16.7). Univariate and multivariate analysis showed the hip to be at greater risk for S. aureus than other joints. Open arthrotomy was a more successful treatment procedure than arthroscopic washout or needle aspiration.13454 - Some of the metrics are blocked by yourconsent settings
Journal ArticlePublication 18-Fluorine-Fluorodeoxyglucose Positron Emission Computer Tomography Imaging in Melioidosis: Valuable but Not Essential.(2025-03-06) ;Bramwell, Joshua ;Kovaleva, Natalia; Melioidosis is an endemic tropical disease caused by . It typically causes pulmonary disease and bacteraemia but can disseminate to cause multi-organ disease. 18-F FDG PET/CT has an evolving role in diagnosing other infectious diseases, especially where the pathogen or extent of infection is challenging to elucidate clinically and with conventional imaging (CT, US and MRI). We present a case series of patients diagnosed with melioidosis who also underwent 18-F FDG PET/CT from December 18th 2018 to September 30th 2022. Indications for imaging were categorised and analysed as to whether 18-F FDG PET/CT changed management over conventional imaging. Twenty-one 18-F FDG PET/CT scans were performed for sixteen patients. Two scans (9.5%) performed for pyrexia of unknown origin changed management in both cases. Twelve scans (57.1%) performed to ascertain the extent of dissemination of melioidosis changed management in only three (25%) cases. Five scans (23.8%) performed to monitor the response to treatment of known foci changed management in all five cases. Five scans (23.8%) performed for suspected or known malignancy changed management in three (60%) cases. 18-F FDG PET/CT is an emerging tool which improves diagnosis and changes the management of melioidosis when applied judiciously and for well-selected indications.1 - Some of the metrics are blocked by yourconsent settings
Journal ArticlePublication 18F-FDG PET/CT in visceral leishmaniasis: uptake patterns in the context of a multiannual outbreak in Northern Italy.(2019-09) ;Zanoni, Lucia ;Varani, Stefania ;Attard, Luciano; ;Vanino, Elisa ;Ortalli, Margherita ;Fonti, Cristina ;Viale, Pierluigi ;Re, Maria Carla ;Fanti, StefanoAmbrosini, ValentinaVisceral leishmaniasis (VL) is the most severe manifestation of the infection caused by the protozoan Leishmania, recently on increase in Italy and Spain. The aim of the study was to describe FDG uptake patterns in VL patients (pts) who underwent 18F-FDG PET/CT. A retrospective monocentric study of pts who underwent FDG PET/CT between 2008 and 2017 and later diagnosed with VL was performed. Semi-quantitative parameters were calculated in FDG-positive lesions: SUVmax, SUVmax spleen/SUVmax liver ratio (SLR), SUVmax focal/diffuse spleen ratio (FDR). Overall, 23 pts were included. PET/CT was negative in 2 immunocompromised pts, positive in 21/23 (91%) [6 spleen only, 2 spleen + nodes, 7 spleen + bone marrow (BM), 4 spleen + BM + nodes, 1 spleen + BM + lung, 1 BM only + nodes, 2 nodes only]. Splenic involvement was demonstrated in 20/23 (87%) pts. Two different splenic patterns were observed: diffuse (13/20 pts, mean spleen SUVmax = 7.3 ± 4.2 [4.0-14.1], mean SLR = 2.2 ± 1.6 [1.3-6.7]) and focal over diffuse (7/20 pts, mean SUVmax = 12.6 ± 4.5 [9.5-20.5], mean SLR = 2.8 ± 0.8 [2.1-4.4], mean FDR = 2.1 ± 0.8 [1.2-3.6]). Extra-splenic FDG-avid findings were detected in 15/21 pts (65%): bone marrow in 13/15 (mean SUVmax = 4.0 ± 1.3 [2.8-6.0]), nodes in 67/15 and lung in 1/15. PET/CT demonstrated splenic FDG uptake in all immunocompetent VL pts; two splenic patterns (diffuse/focal over diffuse) were observed and indistinguishable from splenic involvement by other disorders. The most frequent extra-splenic FDG-positive sites were BM and lymph nodes. Considering the potential disease aggressiveness and recent outbreaks in north-eastern Italy, VL should be considered in the differential diagnosis of FDG-positive splenic findings in pts from endemic areas or reporting travels to endemic countries.15890 - Some of the metrics are blocked by yourconsent settings
Journal ArticlePublication The 1990-1991 outbreak of melioidosis in the Northern Territory of Australia: epidemiology and environmental studies.(1993-09) ;Merianos A ;Patel M ;Lane JM ;Noonan CN ;Sharrock D ;Mock PAFrom November 1990 to June 1991 33 acute cases of melioidosis occurred in the Northern Territory, Australia; 25 cases were reported in the capital city, Darwin. We carried out an epidemiological investigation to exclude a common source outbreak, describe the risk factors for disease, and develop and institute appropriate control measures. We compared population based attack rates among various risk groups using logistic regression, and the demographic, medical and behavioral risk factors for melioidosis by a matched case-control study. Environmental Health Officers collected soil, surface water and cooling tower water specimens for Pseudomonas pseudomallei culture. The crude attack rate of melioidosis during the outbreak was 52 per 100,000. Age, gender, race, diabetes and alcohol abuse were independent risk factors for disease. The relative risk of disease in diabetic patients was 12.9 (95% CI 5.1-32.7; p < 0.001) and 6.7 in alcoholic patients (95% CI 2.9-15.2; p < 0.001). We found no significant difference between cases and controls in matched pair analysis for any of several exposure factors studied. We isolated Pseudomonas pseudomallei from 4% of soil samples and 9% of surface water samples. Our study confirms the importance of host factors in the development of melioidosis, and attempts to quantify the risk of disease during the Darwin epidemic. Pseudomonas pseudomallei is widespread in the soil of urban Darwin.7157 - Some of the metrics are blocked by yourconsent settings
Journal ArticlePublication The 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease.INTRODUCTION: Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) cause significant morbidity and premature mortality among Australian Aboriginal and Torres Strait Islander peoples. RHD Australia has produced a fully updated clinical guideline in response to new knowledge gained since the 2012 edition. The guideline aligns with major international ARF and RHD practice guidelines from the American Heart Association and World Heart Federation to ensure best practice. The GRADE system was used to assess the quality and strength of evidence where appropriate. MAIN RECOMMENDATIONS: The 2020 Australian guideline details best practice care for people with or at risk of ARF and RHD. It provides up-to-date guidance on primordial, primary and secondary prevention, diagnosis and management, preconception and perinatal management of women with RHD, culturally safe practice, provision of a trained and supported Aboriginal and Torres Strait Islander workforce, disease burden, RHD screening, control programs and new technologies. CHANGES IN MANAGEMENT AS A RESULT OF THE GUIDELINE: Key changes include updating of ARF and RHD diagnostic criteria; change in secondary prophylaxis duration; improved pain management for intramuscular injections; and changes to antibiotic regimens for primary prevention. Other changes include an emphasis on provision of culturally appropriate care; updated burden of disease data using linked register and hospitalisations data; primordial prevention strategies to reduce streptococcal infection addressing household overcrowding and personal hygiene; recommendations for population-based echocardiographic screening for RHD in select populations; expanded management guidance for women with RHD or ARF to cover contraception, antenatal, delivery and postnatal care, and to stratify pregnancy risks according to RHD severity; and a priority classification system for presence and severity of RHD to align with appropriate timing of follow-up.6054 - Some of the metrics are blocked by yourconsent settings
Journal ArticlePublication The 2020 IACS Consensus Criteria for the Diagnosis of Scabies.(2020-02-08) ;Engelman D ;Yoshizumi J ;Hay RJ ;Osti M ;Micali G ;Norton S ;Walton S ;Boralevi F ;Bernigaud C ;Bowen AC ;Chang AY ;Chosidow O ;Estrada-Chavez G ;Feldmeier H ;Ishii N ;Lacarrubba F ;Mahé A ;Maurer T ;Mahdi MMA ;Murdoch ME ;Pariser D ;Nair PA ;Rehmus W ;Romani L; ;Tuicakau M ;Walker SL ;Wanat KA ;Whitfeld MJ ;Yotsu RR ;Steer ACFuller CScabies is a common parasitic skin condition that causes considerable morbidity globally. Clinical and epidemiological research for scabies have been limited by a lack of standardisation of diagnostic methods. We aimed to develop consensus criteria for the diagnosis of common scabies that could be implemented in a variety of settings. Consensus diagnostic criteria were developed through a Delphi study of international experts. Detailed recommendations were collected from the expert panel to define the criteria features and guide their implementation. These comments were then combined with a comprehensive review of available literature and opinion of an expanded group of international experts to develop detailed, evidence-based definitions and diagnostic methods. The 2020 IACS Consensus Criteria for the Diagnosis of Scabies include three levels of diagnostic certainty and eight subcategories. Confirmed Scabies (Level A) requires direct visualisation of the mite or its products. Clinical Scabies (Level B) and Suspected Scabies (Level C) rely on clinical assessment of signs and symptoms. Evidence-based, consensus methods for microscopy, visualisation and clinical symptoms and signs were developed, along with a media library. The 2020 IACS Criteria represent a pragmatic, yet robust set of diagnostic features and methods. The criteria may be implemented in a range of research, public health and clinical settings by selecting the appropriate diagnostic levels and subcategories. These criteria may provide greater consistency and standardisation for scabies diagnoses. Validation studies and development of training materials and development of survey methods are now required.11763 - Some of the metrics are blocked by yourconsent settings
Journal ArticlePublication The 2020 International Alliance for the Control of Scabies Consensus Criteria for the Diagnosis of Scabies.(2020-11-01) ;Engelman D ;Yoshizumi J ;Hay RJ ;Osti M ;Micali G ;Norton S ;Walton S ;Boralevi F ;Bernigaud C ;Bowen AC ;Chang AY ;Chosidow O ;Estrada-Chavez G ;Feldmeier H ;Ishii N ;Lacarrubba F ;Mahé A ;Maurer T ;Mahdi MMA ;Murdoch ME ;Pariser D ;Nair PA ;Rehmus W ;Romani L; ;Tuicakau M ;Walker SL ;Wanat KA ;Whitfeld MJ ;Yotsu RR ;Steer ACFuller LCBACKGROUND: Scabies is a common parasitic skin condition that causes considerable morbidity globally. Clinical and epidemiological research for scabies has been limited by a lack of standardization of diagnostic methods. OBJECTIVES: To develop consensus criteria for the diagnosis of common scabies that could be implemented in a variety of settings. METHODS: Consensus diagnostic criteria were developed through a Delphi study with international experts. Detailed recommendations were collected from the expert panel to define the criteria features and guide their implementation. These comments were then combined with a comprehensive review of the available literature and the opinion of an expanded group of international experts to develop detailed, evidence-based definitions and diagnostic methods. RESULTS: The 2020 International Alliance for the Control of Scabies (IACS) Consensus Criteria for the Diagnosis of Scabies include three levels of diagnostic certainty and eight subcategories. Confirmed scabies (level A) requires direct visualization of the mite or its products. Clinical scabies (level B) and suspected scabies (level C) rely on clinical assessment of signs and symptoms. Evidence-based, consensus methods for microscopy, visualization and clinical symptoms and signs were developed, along with a media library. CONCLUSIONS: The 2020 IACS Criteria represent a pragmatic yet robust set of diagnostic features and methods. The criteria may be implemented in a range of research, public health and clinical settings by selecting the appropriate diagnostic levels and subcategories. These criteria may provide greater consistency and standardization for scabies diagnosis. Validation studies, development of training materials and development of survey methods are now required. What is already known about this topic? The diagnosis of scabies is limited by the lack of accurate, objective tests. Microscopy of skin scrapings can confirm the diagnosis, but it is insensitive, invasive and often impractical. Diagnosis usually relies on clinical assessment, although visualization using dermoscopy is becoming increasingly common. These diagnostic methods have not been standardized, hampering the interpretation of findings from clinical research and epidemiological surveys, and the development of scabies control strategies. What does this study add? International consensus diagnostic criteria for common scabies were developed through a Delphi study with global experts. The 2020 International Alliance for the Control of Scabies (IACS) Criteria categorize diagnosis at three levels of diagnostic certainty (confirmed, clinical and suspected scabies) and eight subcategories, and can be adapted to a range of research and public health settings. Detailed definitions and figures are included to aid training and implementation. The 2020 IACS Criteria may facilitate the standardization of scabies diagnosis.5593 - Some of the metrics are blocked by yourconsent settings
Journal ArticlePublication 2020 Review and revision of the 2015 Darwin melioidosis treatment guideline; paradigm drift not shift.(2020-09-20) ;Sullivan RP; ; ;Ward LBACKGROUND: Melioidosis therapy is divided into an intravenous intensive phase and an oral eradication phase. The Darwin melioidosis treatment guideline has evolved over two decades, with over 1150 consecutive patients with culture-confirmed melioidosis managed under the Darwin Prospective Melioidosis Study. The current guideline, published in 2015, has been associated with low rates of recrudescence, relapse and mortality, and together with the treatment trials in Thailand, forms the basis for consensus global guidelines. We aimed to reassess the Darwin guideline and determine if any adjustments to the recommendations better reflect current practice in melioidosis therapy at Royal Darwin Hospital. METHODOLOGY/PRINCIPAL FINDINGS: This retrospective cohort study reviews the characteristics, admission duration, duration of intravenous antibiotics, recrudescence, recurrence and mortality in all patients presenting with first episode culture-confirmed melioidosis in the tropical north of Australia's Northern Territory from 1st October 2012 until 1st January 2017. 234 patients were available for analysis. 16 (6.8%) died during the intensive phase treatment and 6 (2.6%) did not have complete treatment at Royal Darwin Hospital, leaving 212 patients for analysis. Six (2.8%) patients had recrudescence during therapy and 10 (4.7%) had recurrent melioidosis (relapse or new infection) after completion of therapy. Persisting osteomyelitis requiring surgery was an important reason for recrudescence as was unrecognized osteomyelitis for relapse. For patients presenting with an antibiotic duration determining focus of pneumonia, durations of intravenous antibiotics were often prolonged beyond the current 2-week minimum treatment recommendation. Prolongation of therapy in pneumonia mostly occurred in patients presenting with multi-lobar disease or with concurrent blood culture positivity. CONCLUSIONS/SIGNIFICANCE: The 2015 Darwin melioidosis guideline is working well with low rates of recrudescence, relapse and mortality. Based on the practice of the treating clinicians, the 2020 revision of the guideline has been adjusted to include a duration of a minimum of 3 weeks of intravenous antibiotics for those with concurrent bacteraemia and pneumonia involving only a single lobe and those with bilateral and unilateral multi-lobar pneumonias who do not have bacteraemia. We also extend to a minimum of 4 weeks intravenous therapy for those with concurrent bacteraemia and bilateral or unilateral multi-lobar pneumonia.9924 - Some of the metrics are blocked by yourconsent settings
Journal ArticlePublication 2023 Cardiac Society of Australia and New Zealand Expert Position Statement on Catheter and Surgical Ablation for Atrial Fibrillation.(2024-05-02) ;Kistler, Peter M ;Sanders, Prash ;Amarena, John V ;Bain, Chris R ;Chia, Karin M; ;Eslick, Adam T ;Hall, Tanya ;Hopper, Ingrid K ;Kotschet, Emily ;Lim, Han S ;Ling, Liang-Han ;Mahajan, Rajiv ;Marasco, Silvana F ;McGuire, Mark A ;McLellan, Alex J ;Pathak, Rajeev K ;Phillips, Karen P ;Prabhu, Sandeep ;Stiles, Martin K ;Su, Raymond W ;Thomas, Stuart P ;Toy, Tracey ;Watts, Troy W ;Weerasooriya, Rukshen ;Wilsmore, Bradley R ;Wilson, LaurenKalman, Jonathan MCatheter ablation for atrial fibrillation (AF) has increased exponentially in many developed countries, including Australia and New Zealand. This Expert Position Statement on Catheter and Surgical Ablation for Atrial Fibrillation from the Cardiac Society of Australia and New Zealand (CSANZ) recognises healthcare factors, expertise and expenditure relevant to the Australian and New Zealand healthcare environments including considerations of potential implications for First Nations Peoples. The statement is cognisant of international advice but tailored to local conditions and populations, and is intended to be used by electrophysiologists, cardiologists and general physicians across all disciplines caring for patients with AF. They are also intended to provide guidance to healthcare facilities seeking to establish or maintain catheter ablation for AF.5 - Some of the metrics are blocked by yourconsent settings
Journal ArticlePublication 2023 World Heart Federation guidelines for the echocardiographic diagnosis of rheumatic heart disease.(2023-11-02) ;Rwebembera, Joselyn ;Marangou, James ;Mwita, Julius Chacha ;Mocumbi, Ana Olga ;Mota, Cleonice ;Okello, Emmy ;Nascimento, Bruno ;Thorup, Lene ;Beaton, Andrea ;Kado, Joseph; ;Kumar, Raman Krishna ;Lawrenson, John ;Marijon, Eloi ;Mirabel, Mariana ;Nunes, Maria Carmo Pereira ;Piñeiro, Daniel ;Pinto, Fausto ;Ralston, Kate ;Sable, Craig ;Sanyahumbi, Amy ;Saxena, Anita ;Sliwa, Karen ;Steer, Andrew ;Viali, Satupaitea; ;Wilson, Nigel ;Zühlke, LieslRheumatic heart disease (RHD) is an important and preventable cause of morbidity and mortality among children and young adults in low-income and middle-income countries, as well as among certain at-risk populations living in high-income countries. The 2012 World Heart Federation echocardiographic criteria provided a standardized approach for the identification of RHD and facilitated an improvement in early case detection. The 2012 criteria were used to define disease burden in numerous epidemiological studies, but researchers and clinicians have since highlighted limitations that have prompted a revision. In this updated version of the guidelines, we incorporate evidence from a scoping review, an expert panel and end-user feedback and present an approach for active case finding for RHD, including the use of screening and confirmatory criteria. These guidelines also introduce a new stage-based classification for RHD to identify the risk of disease progression. They describe the latest evidence and recommendations on population-based echocardiographic active case finding and risk stratification. Secondary antibiotic prophylaxis, echocardiography equipment and task sharing for RHD active case finding are also discussed. These World Heart Federation 2023 guidelines provide a concise and updated resource for clinical and research applications in RHD-endemic regions.410 - Some of the metrics are blocked by yourconsent settings
Journal ArticlePublication The 5 × 5 path toward rheumatic heart disease control: outcomes from the Third Rheumatic Heart Disease forum.(2015-03-01) ;Johnson, Timothy D ;Grainger Gasser, Alice ;Boardman, Claire; ;Wyber, RosemaryMayosi, Bongani MNo abstract available10209 - Some of the metrics are blocked by yourconsent settings
Book chapterPublication 63 - ScabiesScabies presents as an intensely pruritic rash that predominantly involves hairless and thin skin such as web spaces of the hands and skin creases. Sensitization to mite products is responsible for the itch and therefore symptom onset is usually delayed by weeks in the first infection. Secondary bacterial infection with Staphylococcus aureus and Streptococcus pyogenes is responsible for significant morbidity. Crusted scabies, the most severe form of scabies, presents as a hyperkeratotic rash. Lesions are loaded with mites and such patients are highly infectious. Direct skin-to-skin contact is the most important mode of transmission. Parasitological diagnosis is difficult and therefore clinical diagnosis is usually relied upon, although new diagnostic methods are under development. The most commonly used treatment of choice is topical permethrin cream applied to the whole body. Ivermectin, administered orally, is increasingly being used, including for mass drug administration.52 - Some of the metrics are blocked by yourconsent settings
Audio recordingPublication 94: Of Microbes and Mud“Drs. Genevieve Martin, Catherine Marshall, and Bart Currie from the Royal Darwin Hospital share their approach to Burkholderia pseudomallei aka melioidosis!”28 - Some of the metrics are blocked by yourconsent settings
Journal ArticlePublication A brief description of the epidemiology of dengue in Dili, Timor-Leste, 2018-2022.(2024-04-09) ;Machado, Filipe de Neri; ;Dos Santos, Frederico Bosco Alves ;Mali, Marcelo Amaral ;Pereira Tilman, Ari J ;Soares da Silva, Endang ;Soares, Noel Gama ;Sarmento, Nevio ;Niha, Maria A V ;Soares, Ana Fatima ;Taal, Abdoulie ;Francis, Joshua ;Yan, Jennifer ;Miller, MeggeFlint, JamesDengue virus (DENV) infection causes 390 million infections per year and 40,000 deaths globally. It is endemic in many countries in Asia, Africa, the Americas, the Caribbean, and Oceania. Dengue is endemic in Timor-Leste year-round, but peak transmission occurs during the rainy season. We briefly describe the epidemiology of DENV in the Municipality of Dili between 2018 and 2022. There were 6,234 cases notified, with a mean annual incidence rate of 330 cases per 100,000 population. There were 55 deaths (case fatality rate 0.9%). The peak annual incidence (3,904 cases) occurred in 2022 after an outbreak was declared in January of that year; this outbreak included 760 cases of dengue haemorrhagic fever and 35 deaths. The number of outbreak cases requiring hospital treatment exceeded the usual capacity, but facilities established for coronavirus disease 2019 (COVID-19) isolation and treatment were repurposed to meet this demand. Existing strategies of vector control, minimising breeding sites and promoting early presentation for treatment should continue, as should the utilisation of surveillance systems and treatment facilities established during the COVID-19 pandemic. However, dengue incidence remains high, and other dengue control strategies-including the deployment of Wolbachia-infected mosquitoes-should be considered in Timor-Leste.11 - Some of the metrics are blocked by yourconsent settings
Case ReportsPublication A case of mistaken identity: bile duct masquerading as gallbladder.(2023-01-19) ;Jolly S ;Kundu NLaparoscopic cholecystectomy is a common surgical procedure, with potential for significant morbidity. The incidence of bile duct injuries has increased with the advent of laparoscopy, occurring in up to 1% of cases. Risk of injury increases with aberrant anatomy, acute inflammation and fibrosis. Preventative strategies include obtaining the critical view of safety, using a fundus-first approach and performing a subtotal cholecystectomy in the difficult gallbladder. Although controversy exists for routine cholangiography, its use is helpful in situations of obscure anatomy. We describe the case of a chronically inflamed and unusually small 1.5 cm gallbladder with an obliterated cystic duct. The critical view of safety was not able to be achieved and intraoperative cholangiography enabled identification of aberrant anatomy, with a dilated common duct mistaken as the gallbladder infundibulum. This case highlights the need to be vigilant to structural variation and the utility of selective cholangiography to clarify anatomy.4456 - Some of the metrics are blocked by yourconsent settings
Journal ArticlePublication A clinical approach to chronic respiratory disorders in Aboriginal and Torres Strait Islander Australians in primary care.(2024-12-01) ;Chen, Winnie; Howarth, TimothyChronic respiratory disorders in the adult Aboriginal and Torres Strait Islander population are common, but there is a sparsity of literature detailing an approach to clinical management.This paper describes a clinical approach to chronic respiratory disorders for clinicians working with Aboriginal and Torres Strait Islander people, particularly in the remote Australian context.There are significant differences in the way chronic respiratory diseases manifest in Aboriginal and Torres Strait Islander people compared with non-Indigenous Australians. Chronic obstructive pulmonary disease (COPD), bronchiectasis and asthma often overlap in clinical features, and can be present concurrently. Restrictive impairment on spirometry is common. The presence of bronchodilator response might indicate asthma, but can also be observed in patients with asthma/COPD/bronchiectasis overlap. Because the management of each of these conditions differs, accurate diagnosis and disease severity classification are important, particularly in the prescribing of guideline-recommended inhaled pharmacotherapy.15 - Some of the metrics are blocked by yourconsent settings
Journal ArticlePublication A conserved active site PenA β-lactamase Ambler motif specific for Burkholderia pseudomallei/B. mallei is likely responsible for intrinsic amoxicillin-clavulanic acid sensitivity and facilitates a simple diagnostic PCR assay for melioidosis.(2023-01-12) ;Somprasong N ;Hagen JP ;Sahl JW ;Webb JR ;Hall CM; ;Wagner DM ;Keim PSchweizer HPBurkholderia pseudomallei is a soil- and water-dwelling Gram-negative bacterium that causes melioidosis in humans and animals. Amoxicillin-clavulanic acid (AMC) susceptibility has been hailed as an integral part of the screening algorithm for identification of B. pseudomallei, but the molecular basis for the inherent AMC susceptibility of this bacterium remains undefined. This study showed that B. pseudomallei (and the closely-related B. mallei) wild-type strains are the only Burkholderia spp. that contain a (70)STSK(73) PenA Ambler motif. This motif was present in >99.5% of 1820 analysed B. pseudomallei strains and 100% of 83 analysed B. mallei strains, and is proposed as the likely cause for their inherent AMC sensitivity. The authors developed a polymerase chain reaction (PCR) assay that specifically amplifies the penA(70)ST(S/F)K(73)-containing region from B. pseudomallei and B. mallei, but not from the remaining B. pseudomallei complex species or the (70)STFK(73) region from the closely-related penB of B. cepacia complex species. The abundance and purity of the 193-bp PCR fragment from putative B. pseudomallei isolates from clinical and environmental samples is likely sufficient for reliable confirmation of the presence of B. pseudomallei. The PCR assay is designed to be especially suited for use in resource-constrained areas. While not further explored in this study, the assay may allow diagnosis of putative B. mallei in culture isolates from animal and human samples.3806 - Some of the metrics are blocked by yourconsent settings
Journal ArticlePublication A delayed diagnosis of lymphatic filariasis in a returned traveller from the Philippines.(2025-02-19); ;Pourhadi, Heyadat ;Kahn, Jordan ;Tio, Shio YenAboltins, CraigA 71-year-old Australian-born man with previous extended travel to the Philippines presented with bilateral lymphoedema, fevers and rigors. Examination of a nocturnal blood film revealed microfilariae of , confirming a diagnosis of Bancroftian filariasis. This case highlights the challenges of diagnosing and managing lymphatic filariasis in non-endemic regions.3